scholarly journals Transcranial magnetic resonance-guided focused ultrasound surgery at 1.5T: a technical note

2018 ◽  
Vol 32 (2) ◽  
pp. 132-138 ◽  
Author(s):  
Cesare Gagliardo ◽  
Massimo Midiri ◽  
Roberto Cannella ◽  
Alessandro Napoli ◽  
Paul Wragg ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Focused Ultrasound ◽  
Signal To Noise Ratio ◽  
Technical Note ◽  
The Body ◽  
Imaging Protocol ◽  
Magnetic Resonance Scanner ◽  
Focused Ultrasound Surgery ◽  
Radiofrequency Coil ◽  
Ultrasound System

Magnetic resonance-guided focused ultrasound is one of the emerging non-invasive technologies offering both image guidance and thermal monitoring. In recent years transcranial application of this technology is starting to impact heavily the neuroscience field. We present here the imaging protocol and the technological methods successfully used with a transcranial magnetic resonance-guided focused ultrasound system certified for clinical treatments of functional neurological disorders, integrated for the first time with a 1.5T magnetic resonance scanner. Compared to the body radiofrequency coil (the one commonly used with transcranial magnetic resonance-guided focused ultrasound system integrated with 3T magnetic resonance scanners), the use of a dedicated two channel coil enabled a signal-to-noise ratio gain up to five times higher.

scholarly journals Updated Costs of Uterine Fibroid Treatments Including Focused Ultrasound Surgery

2018 ◽  
Author(s):  
Bijan J. Borah ◽  
Elizabeth A. Stewart
Keyword(s):  
Magnetic Resonance ◽  
Focused Ultrasound ◽  
Treatment Options ◽  
Uterine Fibroids ◽  
Reproductive Age ◽  
Invasive Treatment ◽  
Ultrasound Surgery ◽  
Non Invasive ◽  
Focused Ultrasound Surgery ◽  
Reproductive Age Women

Uterine leiomyomas (fibroids) affect 20–40% of reproductive age women and are the major indication for hysterectomy. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) is a new, potentially disruptive, non-invasive and uterine-sparing treatment option that has been shown to yield similar or better clinical outcomes than other uterine-sparing interventions. However, the costs of MRgFUS and other minimally-invasive treatment options have not been studied using US practice data. This study attempts to fill this void. And since uterine fibroids are the first FDA-approved indication for MRgFUS treatment, this study may also have implications for other indications which are now investigational.

Sign in / Sign up

Export Citation Format

Share Document